Anna Angela Di Tucci

Deferasirox for transfusion‐dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (<scp>GIMEMA MDS</scp>0306 <scp>T</scp>rial)

Emanuele Angelucci, Valeria Santini, Anna Angela Di Tucci et al. · European Journal Of Haematology · 2014 · 95 citations · Full text

Medicine, Hematology, Pharmacology +17

Correction of anemia in a transfusion‐dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade<b>^®</b>, ICL670)

Anna Angela Di Tucci, Roberta Murru, Daniele Alberti et al. · European Journal Of Haematology · 2007 · 63 citations · Full text

Medicine, Hematology, Pharmacotherapy +17

Patient‐reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes

Fabio Efficace, Francesco Cottone, Gregory A. Abel et al. · Cancer · 2017 · 39 citations · Full text

Medicine, Oncology, Clinical Classification Systems +14

Health-related quality of life in transfusion-dependent patients with myelodysplastic syndromes: a prospective study to assess the impact of iron chelation therapy

Fabio Efficace, Valeria Santini, Giorgio La Nasa et al. · BMJ Supportive & Palliative Care · 2014 · 18 citations

Medicine, Hematology, Pharmacotherapy +17